[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,373
  • Shares Outstanding, K 14,564
  • Annual Sales, $ 90 K
  • Annual Income, $ -13,960 K
  • EBIT $ -10 M
  • EBITDA $ -8 M
  • 60-Month Beta 1.18
  • Price/Sales 66.70
  • Price/Cash Flow N/A
  • Price/Book 1.56
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.13
  • Most Recent Earnings $-0.69 on 05/15/26
  • Next Earnings Date 08/13/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.12
  • Number of Estimates 1
  • High Estimate $-0.12
  • Low Estimate $-0.12
  • Prior Year $-3.68
  • Growth Rate Est. (year over year) +96.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2100 +119.00%
on 05/20/26
1.2500 -63.21%
on 06/01/26
+0.1522 (+49.46%)
since 05/11/26
3-Month
0.2100 +119.00%
on 05/20/26
1.6200 -71.61%
on 03/18/26
-0.2154 (-31.90%)
since 03/11/26
52-Week
0.2100 +119.00%
on 05/20/26
20.3500 -97.74%
on 07/28/25
-6.6501 (-93.53%)
since 06/11/25

Most Recent Stories

More News
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules

OCALA, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc . (NYSE American: AIM)  (“AIM” or the “Company”), today announced that it has entered into definitive agreements for a registered...

AIM : 0.4599 (+5.10%)
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

OCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today reported positive progress in a mid-year update from the ongoing...

AIM : 0.4599 (+5.10%)
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness

Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen’s previously published antiviral research Discussion highlights Ampligen’s immune-modulating...

AIM : 0.4599 (+5.10%)
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones

OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced a significant milestone in its pancreatic cancer development...

AIM : 0.4599 (+5.10%)
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration

Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola Company to release Virtual...

AIM : 0.4599 (+5.10%)
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc . (NYSE American: AIM)  (“AIM” or the “Company”, today announced that it has entered into definitive agreements for a registered...

AIM : 0.4599 (+5.10%)
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities

OCALA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced a significant increase in stockholder equity and that the...

AIM : 0.4599 (+5.10%)
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer

Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary...

AIM : 0.4599 (+5.10%)
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds

OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) (“AIM ImmunoTech” or the “Company”), a late-stage biotechnology company focused on the discovery and development...

AIM : 0.4599 (+5.10%)
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

OCALA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced the Final Primary Endpoint Report on Objective Response...

AIM : 0.4599 (+5.10%)

Business Summary

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM...

See More

Key Turning Points

3rd Resistance Point 0.5095
2nd Resistance Point 0.4856
1st Resistance Point 0.4728
Last Price 0.4599
1st Support Level 0.4361
2nd Support Level 0.4122
3rd Support Level 0.3994

See More

52-Week High 20.3500
Fibonacci 61.8% 12.6565
Fibonacci 50% 10.2800
Fibonacci 38.2% 7.9035
Last Price 0.4599
52-Week Low 0.2100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.